Literature DB >> 19937473

Association of C-reactive protein levels and long-term survival after neoadjuvant therapy and esophagectomy for esophageal cancer.

Urs Zingg1, Jens Forberger, Branimir Rajcic, Christopher Langton, Glyn G Jamieson.   

Abstract

BACKGROUND: Preoperative C-reactive protein (CRP) levels have been shown to be prognostic markers of survival in patients undergoing esophagectomy for cancer. No study has evaluated the predictive value for survival of CRP levels after neoadjuvant chemoradiotherapy.
METHODS: Preoperative CRP levels were assessed in patients undergoing neoadjuvant therapy and esophagectomy for cancer. Groups were defined according to normal value cutoffs of the CRP measurements.
RESULTS: Seventy patients had normal CRP, and 20 patients had raised CRP. The groups did not differ in descriptives, comorbidities, white cell counts, pathological data, or morbidity. In-hospital death was higher in the raised CRP group (three versus one patient, p = 0.048). The Kaplan-Meier survival analysis showed a significant survival advantage of patients with normal CRP compared to patients with raised CRP levels (median survival, 65.4 versus 18.7 months; log rank test, p = 0.027). The Cox regression analysis identified three independent prognostic factors for survival: UICC stage (IIB/III versus I/IIA, HR 3.48, p = 0.007), completeness of resection (HR 6.33, p = 0.002), and CRP levels (raised versus normal, HR 5.07, p = 0.001).
CONCLUSION: Preoperative CRP levels are an independent prognostic marker for survival after neoadjuvant treatment in patients with esophageal cancer and may be of value in the re-staging process after neoadjuvant treatment.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19937473     DOI: 10.1007/s11605-009-1113-2

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN: 1091-255X            Impact factor:   3.452


  33 in total

1.  A meta-analysis of randomized controlled trials that compared neoadjuvant chemoradiation and surgery to surgery alone for resectable esophageal cancer.

Authors:  John D Urschel; Hari Vasan
Journal:  Am J Surg       Date:  2003-06       Impact factor: 2.565

2.  Significance of preoperative C-reactive protein as a parameter of the perioperative course and long-term prognosis in squamous cell carcinoma and adenocarcinoma of the oesophagus.

Authors:  Ines Gockel; Kathrin Dirksen; Claudia-M Messow; Theodor Junginger
Journal:  World J Gastroenterol       Date:  2006-06-21       Impact factor: 5.742

3.  Histomorphologic tumor regression and lymph node metastases determine prognosis following neoadjuvant radiochemotherapy for esophageal cancer: implications for response classification.

Authors:  Paul M Schneider; Stephan E Baldus; Ralf Metzger; Martin Kocher; Rudolf Bongartz; Elfriede Bollschweiler; Hartmut Schaefer; Juergen Thiele; Hans P Dienes; Rolf P Mueller; Arnulf H Hoelscher
Journal:  Ann Surg       Date:  2005-11       Impact factor: 12.969

4.  Significance of preoperative elevation of serum C-reactive protein as an indicator of prognosis in esophageal carcinoma.

Authors:  T Nozoe; H Saeki; K Sugimachi
Journal:  Am J Surg       Date:  2001-08       Impact factor: 2.565

5.  Patterns of treatment failure and prognostic factors associated with the treatment of esophageal carcinoma with chemotherapy and radiotherapy either as sole treatment or followed by surgery .

Authors:  P G Gill; J W Denham; G G Jamieson; P G Devitt; E Yeoh; C Olweny
Journal:  J Clin Oncol       Date:  1992-07       Impact factor: 44.544

Review 6.  Biomarkers of response to therapy in oesophago-gastric cancer.

Authors:  K R Fareed; P Kaye; I N Soomro; M Ilyas; S Martin; S L Parsons; S Madhusudan
Journal:  Gut       Date:  2009-01       Impact factor: 23.059

7.  Significant host- and tumor-related factors for predicting prognosis in patients with esophageal carcinoma.

Authors:  Masanori Ikeda; Shoji Natsugoe; Shinichi Ueno; Masamichi Baba; Takashi Aikou
Journal:  Ann Surg       Date:  2003-08       Impact factor: 12.969

8.  Incidence of carcinoma of the oesophagus and gastric cardia. Changes over time and geographical differences.

Authors:  Jens Falk; Hanna Carstens; Lars Lundell; Maria Albertsson
Journal:  Acta Oncol       Date:  2007       Impact factor: 4.089

Review 9.  Factors affecting postoperative course and survival after en bloc resection for esophageal carcinoma.

Authors:  Christophe Mariette; Guillaume Taillier; Isabelle Van Seuningen; Jean-Pierre Triboulet
Journal:  Ann Thorac Surg       Date:  2004-10       Impact factor: 4.330

10.  PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial.

Authors:  Florian Lordick; Katja Ott; Bernd-Joachim Krause; Wolfgang A Weber; Karen Becker; Hubert J Stein; Sylvie Lorenzen; Tibor Schuster; Hinrich Wieder; Ken Herrmann; Rainer Bredenkamp; Heinz Höfler; Ulrich Fink; Christian Peschel; Markus Schwaiger; Jörg R Siewert
Journal:  Lancet Oncol       Date:  2007-09       Impact factor: 41.316

View more
  20 in total

1.  Significance of blood neutrophil-to-lymphocyte ratio for prognostic stratification of patients with gastroesophageal junction adenocarcinoma in the era of the 8th edition of the American Joint Committee on Cancer (AJCC8) staging.

Authors:  Alicia-Marie Conway; Zena Salih; George Papaxoinis; Kimberly Fletcher; Jamie Weaver; Ana Patrao; Robert Noble; Sofia Stamatopoulou; Vikki Owen-Holt; Wasat Mansoor
Journal:  Med Oncol       Date:  2017-05-12       Impact factor: 3.064

2.  Prognostic value of an inflammation-based score in patients undergoing pre-operative chemotherapy followed by surgery for esophageal cancer.

Authors:  Hiroshi Miyata; Makoto Yamasaki; Yukinori Kurokawa; Shuji Takiguchi; Kiyokazu Nakajima; Yoshiyuki Fujiwara; Masaki Mori; Yuichiro Doki
Journal:  Exp Ther Med       Date:  2011-06-30       Impact factor: 2.447

3.  Arginase and C-reactive protein as potential serum-based biomarker of head and neck squamous cell carcinoma patients of north east India.

Authors:  Biswadeep Choudhury; Shilpee Srivastava; Haider H Choudhury; Alokananda Purkayastha; Sumita DuttaGupta; Sankar Kumar Ghosh
Journal:  Tumour Biol       Date:  2014-04-09

4.  Comparative evaluation of serum C-reactive protein (CRP) levels in the different histological subtypes of esophageal cancer (squamous cell carcinoma and adenocarcinoma of esophagus).

Authors:  Marta Lukaszewicz-Zając; Barbara Mroczko; Mirosław Kozłowski; Jacek Nikliński; Jerzy Laudański; Maria Siewko; Maciej Szmitkowski
Journal:  J Clin Lab Anal       Date:  2012-02       Impact factor: 2.352

5.  Role of Postoperative C-Reactive Protein Levels in Predicting Prognosis After Surgical Treatment of Esophageal Cancer.

Authors:  Yuta Ibuki; Yoichi Hamai; Jun Hihara; Manabu Emi; Junya Taomoto; Takaoki Furukawa; Ichiko Yamakita; Tomoaki Kurokawa; Morihito Okada
Journal:  World J Surg       Date:  2017-06       Impact factor: 3.352

6.  C-Reactive Protein and C-Reactive Protein-Based Scores to Predict Survival in Esophageal and Junctional Adenocarcinoma: Systematic Review and Meta-Analysis.

Authors:  Cliona M Lorton; Larissa Higgins; Niamh O'Donoghue; Claire Donohoe; Jim O'Connell; David Mockler; John V Reynolds; Declan Walsh; Joanne Lysaght
Journal:  Ann Surg Oncol       Date:  2021-11-12       Impact factor: 5.344

7.  C-reactive protein to prealbumin ratio: a useful inflammatory and nutritional index for predicting prognosis after curative resection in esophageal squamous cell carcinoma patients.

Authors:  Suguru Maruyama; Akihiko Okamura; Yasukazu Kanie; Kei Sakamoto; Daisuke Fujiwara; Jun Kanamori; Yu Imamura; Koshi Kumagai; Masayuki Watanabe
Journal:  Langenbecks Arch Surg       Date:  2022-04-14       Impact factor: 2.895

8.  C-reactive protein levels: a prognostic marker for patients with head and neck cancer?

Authors:  Astrid L Kruse; Heinz T Luebbers; Klaus W Grätz
Journal:  Head Neck Oncol       Date:  2010-08-02

9.  Association between the inflammatory biomarker, C-reactive protein, and the response to radiochemotherapy in patients with esophageal cancer.

Authors:  Harun Badakhshi; David Kaul; Kuai-LE Zhao
Journal:  Mol Clin Oncol       Date:  2016-01-28

10.  Real-World Efficacy Data and Predictive Clinical Parameters for Treatment Outcomes in Advanced Esophageal Squamous Cell Carcinoma Treated with Immune Checkpoint Inhibitors.

Authors:  Jwa Hoon Kim; Bokyung Ahn; Seung-Mo Hong; Hwoon-Yong Jung; Do Hoon Kim; Kee Don Choi; Ji Yong Ahn; Jeong Hoon Lee; Hee Kyoung Na; Jong Hoon Kim; Yong-Hee Kim; Hyeong Ryul Kim; Hyun Joo Lee; Sung-Bae Kim; Sook Ryun Park
Journal:  Cancer Res Treat       Date:  2021-06-23       Impact factor: 5.036

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.